4 papers
Hematology explores the fascinating world of blood, investigating the cells and proteins that keep our bodies oxygenated and protected from infection. This field delves into everything from how red and white blood cells function to the complex mechanisms behind clotting and immune responses, offering vital insights into conditions ranging from anemia to blood cancers. By understanding these microscopic processes, researchers can develop life-saving treatments for disorders that affect millions globally.
On Gist.Science, we bring these critical discoveries directly to you by monitoring every new preprint published in this category on medRxiv. Our team processes each submission to provide both accessible plain-language overviews and detailed technical summaries, ensuring that complex findings are understandable without losing scientific rigor. Below are the latest papers in hematology, curated to help you stay ahead of the curve in this dynamic area of medical research.
MyeGPT is an AI-powered browser application that enables multiple myeloma researchers to validate hypotheses and visualize results from the complex CoMMpass dataset by converting natural language queries into automated, data-driven analyses without requiring programming skills.
A comparative study conducted at Aniniwaa Medical Centre in Kumasi found that while portable hemoglobin meters offer 100% sensitivity for anemia screening, they significantly underestimate hemoglobin levels and overestimate prevalence compared to the more accurate and reliable fully automated analyser.
This study demonstrates that quantifying HLA evolutionary divergence (HED) in 9/10 mismatched unrelated donor transplants reveals significant within-mismatch heterogeneity and complex, locus-specific interactions that independently predict clinical outcomes such as relapse-free survival, graft-versus-host disease, and mortality, thereby complementing conventional mismatch classification.
This study develops and internally validates the AB-IPI, a novel prognostic score integrating host fitness (albumin), tumor burden (IPI), and tumor biology (BCL2) to improve risk stratification and therapeutic decision-making for R-CHOP-treated diffuse large B-cell lymphoma patients beyond the limitations of the standard IPI.